OBJECTIVE: This 6-week open-label trial of naltrexone was conducted in a preliminary fashion to determine whether naltrexone would be safe, well tolerated, and lead to a reduction in alcohol consumption in adolescents with alcohol dependence. METHOD: Five outpatient treatment-seeking adolescents who met Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria for alcohol dependence were recruited. The Child Schedule for Schizophrenia and Affective Disorders (K-SADS), Structured Clinical Interview for DSM (SCID), and the Family History Questionnaire were administered at baseline. The Time-Line Follow-Back (TLFB) and two craving scales (Adolescent Obsessive Compulsive Drinking Scale [A-OCDS] and a craving analog scale) were administered at baseline and weekly thereafter. Each subject received a 10-day supply of naltrexone (50 mg) and a 100-mg riboflavin capsule. Subjects were instructed to take naltrexone and riboflavin simultaneously. RESULTS: Overall, the average drinks per drinking day (DDD) decreased significantly from baseline to the end of week 6 with an average reduction of 7.61 standard drinks. There was a significant reduction in the average A-OCDS total score, A-OCDS Irresistibility subscale score, and craving analog score. Nausea was the only side-effect reported, and there were no elevations of liver enzymes. Naltrexone was well tolerated by the alcohol-dependent adolescent. CONCLUSIONS: Our data suggest that naltrexone is safe and well tolerated in adolescent alcoholics. Naltrexone may lead to a significant reduction in alcohol consumption and craving in adolescent alcoholics, but larger, randomized, controlled trials are needed.
OBJECTIVE: This 6-week open-label trial of naltrexone was conducted in a preliminary fashion to determine whether naltrexone would be safe, well tolerated, and lead to a reduction in alcohol consumption in adolescents with alcohol dependence. METHOD: Five outpatient treatment-seeking adolescents who met Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria for alcohol dependence were recruited. The Child Schedule for Schizophrenia and Affective Disorders (K-SADS), Structured Clinical Interview for DSM (SCID), and the Family History Questionnaire were administered at baseline. The Time-Line Follow-Back (TLFB) and two craving scales (Adolescent Obsessive Compulsive Drinking Scale [A-OCDS] and a craving analog scale) were administered at baseline and weekly thereafter. Each subject received a 10-day supply of naltrexone (50 mg) and a 100-mg riboflavin capsule. Subjects were instructed to take naltrexone and riboflavin simultaneously. RESULTS: Overall, the average drinks per drinking day (DDD) decreased significantly from baseline to the end of week 6 with an average reduction of 7.61 standard drinks. There was a significant reduction in the average A-OCDS total score, A-OCDS Irresistibility subscale score, and craving analog score. Nausea was the only side-effect reported, and there were no elevations of liver enzymes. Naltrexone was well tolerated by the alcohol-dependent adolescent. CONCLUSIONS: Our data suggest that naltrexone is safe and well tolerated in adolescent alcoholics. Naltrexone may lead to a significant reduction in alcohol consumption and craving in adolescent alcoholics, but larger, randomized, controlled trials are needed.
Authors: John E McGeary; Christianne Esposito-Smythers; Anthony Spirito; Peter M Monti Journal: Pharmacol Biochem Behav Date: 2006-12-15 Impact factor: 3.533
Authors: Robert F Leeman; Rebekka S Palmer; William R Corbin; Denise M Romano; Boris Meandzija; Stephanie S O'Malley Journal: Addict Behav Date: 2008-04-13 Impact factor: 3.913
Authors: Lindsay M Squeglia; Matthew C Fadus; Erin A McClure; Rachel L Tomko; Kevin M Gray Journal: J Child Adolesc Psychopharmacol Date: 2019-04-22 Impact factor: 2.576
Authors: Stephanie S O'Malley; William R Corbin; Robert F Leeman; Kelly S DeMartini; Lisa M Fucito; Jolomi Ikomi; Denise M Romano; Ran Wu; Benjamin A Toll; Kenneth J Sher; Ralitza Gueorguieva; Henry R Kranzler Journal: J Clin Psychiatry Date: 2015-02 Impact factor: 4.384
Authors: Sandra A Springer; Angela Di Paola; Marwan M Azar; Russell Barbour; Archana Krishnan; Frederick L Altice Journal: Drug Alcohol Depend Date: 2017-03-10 Impact factor: 4.492
Authors: Robert Miranda; Lara Ray; Alexander Blanchard; Elizabeth K Reynolds; Peter M Monti; Thomas Chun; Alicia Justus; Robert M Swift; Jennifer Tidey; Chad J Gwaltney; Jason Ramirez Journal: Addict Biol Date: 2013-03-13 Impact factor: 4.280